Phase 3 TRIUMPH-1 Results (Reported 21 May 2026) On 21 May 2026, Eli Lilly reported topline results from TRIUMPH-1 , the pivotal Phase 3 obesity trial, the first Phase 3 efficacy readout in the retatrutide programme
All of these models assume perfect dose accuracy
Sections were mounted in a Sequenza immunostaining system and incubated with peroxidase blocking solution for 10 min, then rinsed in PBS (pH 7.6)
Through the use of ingredients like glutathione, vitamin C, collagen , alpha-arbutin, and herbal extracts, these capsules work by inhibiting melanin production and promoting a lighter and more even complexion
however, high doses of ALCA increased liver mitochondrial oxidant production [143]
The mean baseline body weight was 235 pounds and the trial lasted 68 weeks